Ask AI

Capsule Summaries

Share

Program Content

Activities

IMforte Safety Analysis
IMforte: Expanded Safety Analysis of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

FLAURA2 Final OS
FLAURA2: Final Overall Survival of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

Beamion LUNG 1 Brain Mets
Beamion LUNG-1: Phase Ib Study of Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2025

ARROS 1
ARROS-1: Phase I/II Study of Zidesamtinib for Patients With Advanced ROS1+ NSCLC After Prior ROS1 TKI
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2025

DeLLphi 303 Maintenance
DeLLphi-303: Updated Phase Ib Results of 1L Maintenance Therapy With Tarlatamab + PD-L1 Inhibitor in Extensive-Stage SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.